Jiang Tao, Zhang Jiahui, Ruan Beite, Xi Xiaobing, Yang Zhuo, Liu Jianmin, Zhao Hongyan, Xu Xing, Jiang Min
Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chin Med. 2024 Mar 1;19(1):37. doi: 10.1186/s13020-024-00909-x.
Osteoarthritis (OA) is a prevalent global health concern associated with the loss of articular cartilage and subchondral bone. The lack of disease-modifying drugs for OA necessitates the exploration of novel therapeutic options. Our previous study has demonstrated that traditional Chinese medical herb Trachelospermum jasminoides (Lindl.) Lem. extract suppressed osteoclastogenesis and identified trachelogenin (TCG) as a representative compound. Here, we delved into TCG's potential to alleviate OA.
We initially validated the in vivo efficacy of TCG in alleviating OA using a rat OA model. Subsequently, we isolated primary bone marrow-derived macrophages in vitro to investigate TCG's impact on osteoclastogenesis. We further employed a small molecule pull-down assay to verify TCG's binding target within osteoclasts. Finally, we isolated primary mouse chondrocytes in vitro to study TCG's regulatory effects and mechanisms on chondrocyte survival.
TCG preserved subchondral bone integrity and protected articular cartilage in a rat OA model. Subsequently, in vitro experiments unveiled TCG's capability to inhibit osteoclastogenesis and function through binding to Ras association proximate 1 (Rap1) and inhibiting its activation. Further study demonstrated that TCG inhibited Rap1/integrin αvβ3/c-Src/Pyk2 signaling cascade, and consequently led to failed F-actin ring formation. Besides, TCG promoted the proliferation of mouse primary chondrocytes while suppressing apoptosis in vitro. This is attributed to TCG's ability to upregulate HIF1α, thereby promoting glycolysis.
TCG exerted inhibitory effects on osteoclastogenesis through binding to Rap1 and inhibiting Rap1 activation, consequently preventing subchondral bone loss. Moreover, TCG enhanced chondrocyte survival by upregulating HIF1α and promoting glycolysis. These dual mechanisms collectively provide a novel approach to prevented against cartilage degradation.
骨关节炎（OA）是一个普遍存在的全球健康问题，与关节软骨和软骨下骨的丢失相关。缺乏用于OA的疾病修饰药物使得探索新的治疗选择成为必要。我们之前的研究表明，传统中药络石藤提取物抑制破骨细胞生成，并确定络石苷元（TCG）为代表性化合物。在此，我们深入研究了TCG缓解OA的潜力。
我们首先使用大鼠OA模型验证了TCG在缓解OA方面的体内疗效。随后，我们在体外分离原代骨髓来源的巨噬细胞，以研究TCG对破骨细胞生成的影响。我们进一步采用小分子下拉试验来验证TCG在破骨细胞内的结合靶点。最后，我们在体外分离原代小鼠软骨细胞，以研究TCG对软骨细胞存活的调节作用及其机制。
在大鼠OA模型中，TCG保持了软骨下骨的完整性并保护了关节软骨。随后，体外实验揭示了TCG通过与Ras相关邻近蛋白1（Rap1）结合并抑制其激活来抑制破骨细胞生成和功能的能力。进一步的研究表明，TCG抑制Rap1/整合素αvβ3/c-Src/Pyk2信号级联，从而导致F-肌动蛋白环形成失败。此外，TCG在体外促进小鼠原代软骨细胞的增殖，同时抑制细胞凋亡。这归因于TCG上调缺氧诱导因子1α（HIF1α）的能力，从而促进糖酵解。
TCG通过与Rap一结合并抑制Rap1激活对破骨细胞生成产生抑制作用，从而防止软骨下骨丢失。此外，TCG通过上调HIF1α和促进糖酵解增强了软骨细胞的存活。这些双重机制共同提供了一种预防软骨降解的新方法。
Zotero 插件
